Roth Capital raised the firm’s price target on Biofrontera Inc. (BFRI) to $10 from $8 and keeps a Buy rating on the shares. The firm notes Biofrontera Inc. acquired full U.S. Ameluz and RhodoLED rights from former parent company Biofrontera AG, which, when combined with the $11M investment from existing institutional investors, funds Biofrontera Inc. to profitability.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BFRI:
- Biofrontera Inc. restructures relationship with Biofrontera AG
- Biofrontera Holds Annual Stockholders Meeting, Key Decisions Made
- Biofrontera Inc. Negotiates Cooperation Changes with Biofrontera AG
- Biofrontera Inc. confirms talks on possible combination with Biofrontera AG
- Biofrontera Updates Proxy Statement for 2025 Meeting